Oxidative stress supposedly plays a role in the pathogenesis of Parkinson's disease (PD). Uric acid (UA), a powerful antioxidant, is lowered in PD while allantoin, the oxidation product of UA and known biomarker of oxidative stress, was not systematically studied in PD. We aim to compare serum and cerebrospinal fluid (CSF) levels of UA, allantoin, and allantoin/UA ratio in de novo PD patients and controls, and evaluate their associations with clinical severity and the degree of substantia nigra degeneration in PD. We measured serum and CSF levels of UA, allantoin, and allantoin/UA ratio in 86 PD patients (33 females, mean age 57.9 (SD 12.6) years; CSF levels were assessed in 51 patients) and in 40 controls (19 females, 56.7 (14.1) years). PD patients were examined using Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS), Montreal Cognitive Assessment (MoCA), Scales for Outcomes in Parkinson Disease-Autonomic (SCOPA-AUT), the University of Pennsylvania Smell Identification Test (UPSIT), one-night video-polysomnography, and dopamine transporter single-photon emission computed tomography (DAT-SPECT). Serum allantoin and allantoin/UA ratio were significantly increased in the PD group compared to controls (p < 0.001 and p = 0.002, respectively). Allantoin/UA ratios in serum and CSF were positively associated with the SCOPA-AUT score (p = 0.005 and 0.031, respectively) and RBD presence (p = 0.044 and 0.028, respectively). In conclusion, serum allantoin and allantoin/UA ratio are elevated in patients with de novo PD. Allantoin/UA ratio in serum and CSF is associated with autonomic dysfunction and RBD presence, indicating that higher systemic oxidative stress occurs in PD patients with more diffuse neurodegenerative changes.

Department of Analytical Chemistry Faculty of Science Charles University Prague Czech Republic

Department of Neurology and Centre of Clinical Neuroscience 1st Faculty of Medicine Charles University and General University Hospital Prague Czech Republic

Department of Physical and Macromolecular Chemistry Faculty of Science Charles University Prague Czech Republic

Department of Radiology 1st Faculty of Medicine Charles University and General University Hospital Prague Czech Republic

Institute of Medical Biochemistry and Laboratory Diagnostics 1st Faculty of Medicine Charles University and General University Hospital Prague Czech Republic

Institute of Nuclear Medicine 1st Faculty of Medicine Charles University and General University Hospital Prague Czech Republic

Institute of Rheumatology Prague Czech Republic; Department of Rheumatology 1st Faculty of Medicine Charles University Prague Czech Republic

Zobrazit více v PubMed

Spillantini MG, et al. Alpha-synuclein in Lewy bodies. Nature. 1997;388:839–840. doi: 10.1038/42166. PubMed DOI

Fereshtehnejad SM, Zeighami Y, Dagher A, Postuma RB. Clinical criteria for subtyping Parkinson’s disease: biomarkers and longitudinal progression. Brain. 2017;140:1959–1976. doi: 10.1093/brain/awx118. PubMed DOI

Riboldi GM, Russo MJ, Pan L, Watkins K, Kang UJ. Dysautonomia and REM sleep behavior disorder contributions to progression of Parkinson’s disease phenotypes. NPJ Parkinsons Dis. 2022;8:110. doi: 10.1038/s41531-022-00373-0. PubMed DOI PMC

Trist BG, Hare DJ, Double KL. Oxidative stress in the aging substantia nigra and the etiology of Parkinson’s disease. Aging Cell. 2019;18:e13031. doi: 10.1111/acel.13031. PubMed DOI PMC

Yu Z, et al. The significance of uric acid in the diagnosis and treatment of Parkinson disease: An updated systemic review. Med. (Baltim.) 2017;96:e8502. doi: 10.1097/MD.0000000000008502. PubMed DOI PMC

Sies H. Oxidative stress: a concept in redox biology and medicine. Redox Biol. 2015;4:180–183. doi: 10.1016/j.redox.2015.01.002. PubMed DOI PMC

Ames BN, Cathcart R, Schwiers E, Hochstein P. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc. Natl Acad. Sci. 1981;78:6858–6862. doi: 10.1073/pnas.78.11.6858. PubMed DOI PMC

Wen M, et al. Serum uric acid levels in patients with Parkinson’s disease: A meta-analysis. PLoS One. 2017;12:e0173731. doi: 10.1371/journal.pone.0173731. PubMed DOI PMC

Ascherio A, et al. Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch. Neurol. 2009;66:1460–1468. doi: 10.1001/archneurol.2009.247. PubMed DOI PMC

Schwarzschild MA, et al. Serum Urate as a Predictor of Clinical and Radiographic Progression in Parkinson Disease. Arch. Neurol. 2008;65:716–723. doi: 10.1001/archneur.2008.65.6.nct70003. PubMed DOI PMC

Chang H, Wang B, Shi Y, Zhu R. Dose-response meta-analysis on urate, gout, and the risk for Parkinson’s disease. npj Parkinson’s Dis. 2022;8:160. doi: 10.1038/s41531-022-00433-5. PubMed DOI PMC

Cipriani S, et al. Urate and its transgenic depletion modulate neuronal vulnerability in a cellular model of Parkinson’s disease. PLoS One. 2012;7:e37331. doi: 10.1371/journal.pone.0037331. PubMed DOI PMC

Chen X, et al. Disrupted and transgenic urate oxidase alter urate and dopaminergic neurodegeneration. Proc. Natl Acad. Sci. 2013;110:300–305. doi: 10.1073/pnas.1217296110. PubMed DOI PMC

Kaur H, Halliwell B. Action of biologically-relevant oxidizing species upon uric acid. Identification of uric acid oxidation products. Chem.-Biol. Interact. 1990;73:235–247. doi: 10.1016/0009-2797(90)90006-9. PubMed DOI

Grootveld M, Halliwell B. Measurement of allantoin and uric acid in human body fluids. A potential index of free-radical reactions in vivo? Biochem. J. 1987;243:803–808. doi: 10.1042/bj2430803. PubMed DOI PMC

Dalbeth N, Gosling AL, Gaffo A, Abhishek A. Gout. Lancet. 2021;397:1843–1855. doi: 10.1016/S0140-6736(21)00569-9. PubMed DOI

Sampat R, et al. Potential mechanisms for low uric acid in Parkinson disease. J. Neural Transm. 2016;123:365–370. doi: 10.1007/s00702-015-1503-4. PubMed DOI PMC

Hasíková L, et al. Patients with REM sleep behavior disorder have higher serum levels of allantoin. Parkinsonism Relat. Disord. 2021;90:38–43. doi: 10.1016/j.parkreldis.2021.07.031. PubMed DOI

Simuni T, et al. Baseline prevalence and longitudinal evolution of non-motor symptoms in early Parkinson’s disease: the PPMI cohort. J. Neurol. Neurosurg. Psychiatry. 2018;89:78–88. doi: 10.1136/jnnp-2017-316213. PubMed DOI PMC

Mollenhauer B, et al. Nonmotor and diagnostic findings in subjects with de novo Parkinson disease of the DeNoPa cohort. Neurology. 2013;81:1226–1234. doi: 10.1212/WNL.0b013e3182a6cbd5. PubMed DOI

Kopecek M, et al. Montreal cognitive assessment (MoCA): Normative data for old and very old Czech adults. Appl Neuropsychol. Adult. 2017;24:23–29. doi: 10.1080/23279095.2015.1065261. PubMed DOI

Kanďár R. The ratio of oxidized and reduced forms of selected antioxidants as a possible marker of oxidative stress in humans. Biomed. Chromatogr. 2016;30:13–28. doi: 10.1002/bmc.3529. PubMed DOI

Kozlik P, Hasikova L, Stiburkova B, Zavada J, Kalikova K. Rapid and reliable HILIC-MS/MS method for monitoring allantoin as a biomarker of oxidative stress. Anal. Biochem. 2020;589:113509. doi: 10.1016/j.ab.2019.113509. PubMed DOI

Kastenbauer S, Koedel U, Becker BF, Pfister HW. Oxidative stress in bacterial meningitis in humans. Neurology. 2002;58:186–191. doi: 10.1212/WNL.58.2.186. PubMed DOI

Yardim‐Akaydin S, Sepici A, Özkan Y, Şimşek B, Sepici V. Evaluation of allantoin levels as a new marker of oxidative stress in Behçet’s disease. Scand. J. Rheumatol. 2006;35:61–64. doi: 10.1080/03009740510026878. PubMed DOI

Kand'ár R, Žáková P, Mužáková V. Monitoring of antioxidant properties of uric acid in humans for a consideration measuring of levels of allantoin in plasma by liquid chromatography. Clin. Chim. Acta. 2006;365:249–256. doi: 10.1016/j.cca.2005.09.002. PubMed DOI

Wei Z, Li X, Li X, Liu Q, Cheng Y. Oxidative Stress in Parkinson’s Disease: A Systematic Review and Meta-Analysis. Front Mol. Neurosci. 2018;11:236. doi: 10.3389/fnmol.2018.00236. PubMed DOI PMC

Shen L, Ji HF. Low uric acid levels in patients with Parkinson’s disease: evidence from meta-analysis. BMJ Open. 2013;3:e003620. doi: 10.1136/bmjopen-2013-003620. PubMed DOI PMC

Koros C, et al. Serum uric acid level as a putative biomarker in Parkinson’s disease patients carrying GBA1 mutations: 2-Year data from the PPMI study. Parkinsonism Relat. Disord. 2021;84:1–4. doi: 10.1016/j.parkreldis.2020.12.020. PubMed DOI

Schwarzschild MA, et al. Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3 Randomized Clinical Trial. Jama. 2021;326:926–939. doi: 10.1001/jama.2021.10207. PubMed DOI PMC

Coneys R, Storm CS, Kia DA, Almramhi M, Wood NW. Mendelian Randomisation Finds No Causal Association between Urate and Parkinson’s Disease Progression. Mov. Disord. 2021;36:2182–2187. doi: 10.1002/mds.28662. PubMed DOI

Grażyńska, A. et al. The Influence of Serum Uric Acid Level on Non-Motor Symptoms Occurrence and Severity in Patients with Idiopathic Parkinson’s Disease and Atypical Parkinsonisms-A Systematic Review. Medicina (Kaunas)57, (2021). PubMed PMC

De Pablo-Fernandez E, et al. Association of Autonomic Dysfunction With Disease Progression and Survival in Parkinson Disease. JAMA Neurol. 2017;74:970–976. doi: 10.1001/jamaneurol.2017.1125. PubMed DOI PMC

Chen Z, Li G, Liu J. Autonomic dysfunction in Parkinson’s disease: Implications for pathophysiology, diagnosis, and treatment. Neurobiol. Dis. 2020;134:104700. doi: 10.1016/j.nbd.2019.104700. PubMed DOI

Moccia M, et al. Is serum uric acid related to non-motor symptoms in de-novo Parkinson’s disease patients? Parkinsonism Relat. Disord. 2014;20:772–775. doi: 10.1016/j.parkreldis.2014.03.016. PubMed DOI

Bowman GL, Shannon J, Frei B, Kaye JA, Quinn JF. Uric acid as a CNS antioxidant. J. Alzheimers Dis. 2010;19:1331–1336. doi: 10.3233/JAD-2010-1330. PubMed DOI PMC

Becker BF, Kastenbauer S, Ködel U, Kiesl D, Pfister HW. Urate oxidation in CSF and blood of patients with inflammatory disorders of the nervous system. Nucleosides Nucleotides Nucleic Acids. 2004;23:1201–1204. doi: 10.1081/NCN-200027469. PubMed DOI

Dušek P, et al. Clinical characteristics of newly diagnosed Parkinson’s disease patients included in the longitudinal BIO-PD study. Česká a slovenská neurologie a neurochirurgie. 2020;83:633–639. doi: 10.48095/cccsnn2020633. DOI

Postuma RB, et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov. Disord. 2015;30:1591–1601. doi: 10.1002/mds.26424. PubMed DOI

Teunissen CE, et al. A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology. 2009;73:1914–1922. doi: 10.1212/WNL.0b013e3181c47cc2. PubMed DOI PMC

Goetz CG, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov. Disord. 2008;23:2129–2170. doi: 10.1002/mds.22340. PubMed DOI

Visser M, Marinus J, Stiggelbout AM, Van Hilten JJ. Assessment of autonomic dysfunction in Parkinson’s disease: the SCOPA-AUT. Mov. Disord. 2004;19:1306–1312. doi: 10.1002/mds.20153. PubMed DOI

Doty RL, Shaman P, Dann M. Development of the University of Pennsylvania Smell Identification Test: a standardized microencapsulated test of olfactory function. Physiol. Behav. 1984;32:489–502. doi: 10.1016/0031-9384(84)90269-5. PubMed DOI

Darcourt J, et al. EANM procedure guidelines for brain neurotransmission SPECT using (123)I-labelled dopamine transporter ligands, version 2. Eur. J. Nucl. Med Mol. Imaging. 2010;37:443–450. doi: 10.1007/s00259-009-1267-x. PubMed DOI

Dušek P, et al. Relations of non-motor symptoms and dopamine transporter binding in REM sleep behavior disorder. Sci. Rep. 2019;9:15463. doi: 10.1038/s41598-019-51710-y. PubMed DOI PMC

Calvini P, et al. The basal ganglia matching tools package for striatal uptake semi-quantification: description and validation. Eur. J. Nucl. Med Mol. Imaging. 2007;34:1240–1253. doi: 10.1007/s00259-006-0357-2. PubMed DOI

American Academy of Sleep, M. International classification of sleep disorders, (American Academy of Sleep Medicine, Darien, IL, 2014).

Enroth S, Hallmans G, Grankvist K, Gyllensten U. Effects of Long-Term Storage Time and Original Sampling Month on Biobank Plasma Protein Concentrations. EBioMedicine. 2016;12:309–314. doi: 10.1016/j.ebiom.2016.08.038. PubMed DOI PMC